BEBT-108/109

BEBT-108/109
  
  
BEBT-108 and BEBT-109 are third generation EGFR inhibitors developed on the basis of Osimertinib (AZD9291). The company wholly owns world-wide IP rights on their chemical structures. Their inhibitory activities against EGFR(T790M) are significantly stronger than AZD9291. In addition, their selectivities against mutant EGFR are over 1000-fold than the wild type EGFR. Furthermore, as a covalent irreversible EGFR inhibitor, they have improved DM/PK activities and significantly better safety profiles. They demonstrated potent activities against various tumor models with EGFR mutations. Therefore, they have the potential to be best-in-class 3rd generation EGFR inhibitors.